Lazard Asset Management LLC Purchases 96,689 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Lazard Asset Management LLC lifted its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 38.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 348,599 shares of the biotechnology company’s stock after purchasing an additional 96,689 shares during the quarter. Lazard Asset Management LLC’s holdings in ADMA Biologics were worth $5,977,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Perpetual Ltd acquired a new stake in shares of ADMA Biologics in the 4th quarter valued at about $62,300,000. Allspring Global Investments Holdings LLC boosted its position in shares of ADMA Biologics by 1,144.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after buying an additional 2,613,482 shares during the period. B Group Inc. acquired a new position in shares of ADMA Biologics during the fourth quarter worth about $39,231,000. Raymond James Financial Inc. acquired a new position in shares of ADMA Biologics during the fourth quarter worth about $19,076,000. Finally, Principal Financial Group Inc. boosted its position in shares of ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after buying an additional 1,059,394 shares during the period. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Down 1.4%

Shares of NASDAQ:ADMA opened at $19.20 on Friday. The company’s 50-day moving average price is $20.44 and its two-hundred day moving average price is $18.82. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a one year low of $8.91 and a one year high of $25.67. The stock has a market capitalization of $4.56 billion, a PE ratio of 68.57 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company’s quarterly revenue was up 40.2% compared to the same quarter last year. During the same period last year, the firm earned $0.08 earnings per share. On average, equities analysts forecast that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ADMA. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th. Raymond James boosted their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research report on Thursday, May 8th. Finally, StockNews.com cut shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.